Patrick W. McLaughlin, MD, Author at Grand Rounds in Urology

Patrick W. McLaughlin, MD

University of Michigan Radiation Oncology Associates

Novi, Michigan

Bill McLaughlin, MD, is a Professor of Radiation Oncology at University of Michigan Medicine. He is the Medical Director of Community Practices at Providence Hospital in Southfield, Michigan, and the Assarian Cancer Center in Novi, Michigan. Dr. McLaughlin is a board-certified radiation oncologist with a special interest in prostate cancer. Dr. McLaughlin is a member of the American Society for Therapeutic Radiology and Oncology (ASTRO) and the American Brachytherapy Society (ABS). Dr. McLaughlin pioneered MRI-based treatment planning for prostate implants and external beam therapy. Incorporating MRI imaging led to the development of vessel-sparing radiation analogous to nerve-sparing prostatectomy. MRI-based evaluation post implant has improved the accuracy of implant checking and improved the quality of prostate implants. These techniques have vastly improved the quality of life for men with prostate cancer. The results of this research were published in the International Journal of Radiation Oncology, Biology, and Physics. Dr. McLaughlin participated in the design of the Assarian Cancer Center, which features an integrated healing arts center and a program to improve patient and family support at all stages of the cancer experience.

Talks by Patrick W. McLaughlin, MD

Hormone Therapy in High Risk Prostate Cancer

Posted by Patrick W. McLaughlin, MD | Aug 2019

Patrick W. McLaughlin, MD, discusses balancing the therapeutic effects of androgen deprivation therapy (ADT) with the impact of quality of life (QOL). He examines the best timing and radiotherapy regimen combination to pair with ADT, as well as properly assessing individual patients’ risk factors and disease severity when choosing treatment options.

The Modern Definition of Successful Cancer Treatment – Cure with Quality of Life

Posted by Patrick W. McLaughlin, MD | Aug 2019

Patrick W. McLaughlin, MD, discusses the balance of cure versus quality-of-life when treating prostate cancer patients. He details his approach to ensuring optimal patient-preferred outcomes using physician-as-advocate decision-making, as well as individual anatomical and tumor characteristics in guiding treatment planning.

The Staggering Benefit of PSA Screening in Potentially Lethal Prostate Cancer

Posted by Patrick W. McLaughlin, MD | Jul 2019

Patrick W. McLaughlin, MD, discusses the limitations of evidence that provide the basis for the United States Preventive Services Task Force’s (USPSTF’s) negative gradings for PSA screening. He argues that in the modern era, with the currently-available curative therapy for most lethal prostate cancers, intensive screening can allow early enough detection to provide patients opportunities for a cure.